ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematology Annual Meeting

  • Post author:
  • Post category:Newsroom

ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the acceptance of an abstract with…

Continue ReadingERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematology Annual Meeting

ERYTECH Announces Publication of a Paper on Red-Blood Cell Characterization in High Impact Peer Reviewed Journal

  • Post author:
  • Post category:Newsroom

The Paper "Multiparametric characterization of red blood cell physiology after hypotonic dialysis based drug encapsulation process" is available in the October 2021 (Volume 11, Issue 10) of Acta Pharmaceutica Sinica…

Continue ReadingERYTECH Announces Publication of a Paper on Red-Blood Cell Characterization in High Impact Peer Reviewed Journal

ERYTECH to Present at the 12th Annual Jefferies Global London Healthcare Conference

  • Post author:
  • Post category:Newsroom

In-Person Dates: November 16th-17th • Virtual Dates: November 18th-19th ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood…

Continue ReadingERYTECH to Present at the 12th Annual Jefferies Global London Healthcare Conference

ERYTECH Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase in Patients with Second-line Advanced Pancreatic Cancer

  • Post author:
  • Post category:Newsroom

Management to host Conference Call on Monday, October 25, at 8:30am EDT/ 2:30pm CEST ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic…

Continue ReadingERYTECH Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase in Patients with Second-line Advanced Pancreatic Cancer

ERYTECH Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

  • Post author:
  • Post category:Newsroom

No dose-limiting toxicity (DLT) reported in first two dose cohorts, leading to declaration of the maximum tolerated dose (MTD) at 100 U/kgEncouraging clinical activity observed in first patients  ERYTECH Pharma…

Continue ReadingERYTECH Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

ERYTECH to Participate in the HealthTech Innovation Days (HTID) by France Biotech

  • Post author:
  • Post category:Newsroom

ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the company’s participation in one-on-one investor…

Continue ReadingERYTECH to Participate in the HealthTech Innovation Days (HTID) by France Biotech
Menu